We talk about rare diseases like they’re a category, a bucket labeled “uncommon,” but most of us don’t really grasp what that means. There are over 7,000 identified rare diseases. Some affect tens of thousands. Others—like this one—exist on the very edge of medical visibility. The thing is, defining “rarest” isn’t just about counting patients. It’s about detection, diagnosis, and the brutal economics of studying something that may never show up again.
Defining “Rare” in Medicine: How We Count the Unseen
Let’s start with a basic truth: rarity is relative. In the U.S., a rare disease affects fewer than 200,000 people. In Europe, it’s fewer than 1 in 2,000. But that doesn’t mean all rare diseases are equally rare. Some hover just below the threshold. Others—like Ribose-5-phosphate isomerase deficiency—lie so far beneath it they might as well be theoretical.
One Case and Counting: The Singular Patient
In 2004, a Dutch child was diagnosed with developmental delays, seizures, and leukoencephalopathy—white matter deterioration in the brain. Genetic testing revealed a mutation in the RPIA gene, responsible for a critical enzyme in the pentose phosphate pathway. Without it, cells can’t produce ribose-5-phosphate, a building block for DNA and RNA. This child remains the only known human with this condition. No siblings. No new cases in two decades. Ribose-5-phosphate isomerase deficiency isn’t just rare. It’s a medical singleton.
And that’s exactly where things get philosophically murky. Can a disease exist with only one case? Some experts argue yes—if the mechanism is biologically plausible and confirmed. Others say we need replication. But science doesn’t always wait for patterns. Sometimes it starts with an anomaly.
Rarity vs. Undiagnosed: The Diagnostic Desert
Here’s what people don’t think about enough: just because we’ve only seen one case doesn’t mean there aren’t others. Many ultra-rare conditions go undiagnosed because symptoms mimic more common disorders. A child in rural Mongolia with neurological issues won’t get whole-exome sequencing. They’ll get misdiagnosed with cerebral palsy or epilepsy. So is Ribose-5-phosphate isomerase deficiency truly the rarest, or just the rarest we’ve caught?
The issue remains: detection bias. Wealthy countries diagnose more rare diseases—not because they have more, but because they look harder. That skews our entire understanding of rarity. And let’s be clear about this: the rarest disease might already exist in someone’s body, undiscovered, unrecorded, and utterly alone in their suffering.
Other Contenders in the Race for Rarest
Calling Ribose-5-phosphate isomerase deficiency the rarest feels almost unfair—it’s not even a contest. But for context, let’s look at other diseases with only a handful of known cases. These are not “rare.” They are statistical ghosts.
Katayama Disease: When the Immune System Attacks After Treatment
Also known as acute schistosomiasis, this reaction occurs in people infected with the parasitic worm Schistosoma—usually in sub-Saharan Africa or Southeast Asia. But Katayama disease isn’t the infection itself. It’s a dangerous immune overreaction that can happen days or weeks after treatment. Fever, cough, liver enlargement, even meningitis-like symptoms. It affects maybe 10% of first-time infections—so why is it so rare?
Because most cases go undiagnosed. In areas where schistosomiasis is endemic, people often don’t get treated, or they get treated too late. The few documented cases of pure Katayama disease—without co-infections or complications—are counted on one hand.
Fields Disease: The Mystery That Stumped Doctors for Decades
Named after the Fields family in Canada, this neuromuscular disorder killed four sisters between 1966 and 1978. Symptoms: progressive muscle weakness, respiratory failure, no known cause. For years, it was a medical enigma. Then, in 2015, researchers finally identified a mutation in the SLC18A2 gene. Only five cases ever confirmed. One family. One tragic lineage. And then—silence. No new mutations detected. Is it extinct? Or just waiting?
Because here’s the twist: some ultra-rare diseases may only appear once. A spontaneous mutation. A genetic accident. No inheritance. No spread. Gone before we even named it.
Ribose-5-Phosphate Isomerase Deficiency: Inside the Science
The pentose phosphate pathway isn’t something you learn in high school biology. It’s not as flashy as DNA replication or photosynthesis. Yet it’s vital. It generates NADPH (a cellular antioxidant) and ribose-5-phosphate (for nucleotide synthesis). Without it, cells—especially brain cells—can’t maintain redox balance or repair DNA.
The RPIA gene codes for ribose-5-phosphate isomerase, the enzyme that converts ribulose-5-phosphate into ribose-5-phosphate. When it’s defective, the pathway stalls. Metabolites build up. Neurological damage follows. In the Dutch patient, MRI scans showed widespread white matter loss. Metabolomic screening revealed abnormal sugar alcohols in the urine—a clue so subtle most labs wouldn’t notice.
We’re far from having treatments. Gene therapy? Theoretically possible. But with one patient, who funds the trials? Who runs the phase I studies? The economics don’t work. That changes everything—or rather, prevents everything.
Metabolic Orphans: The Challenge of Studying One-Person Diseases
Drug development costs an average of $2.6 billion per approved therapy. For a disease with one case, the ROI is negative infinity. That’s why so many rare diseases fall into the “orphan” category—not just medically, but ethically. Pharmaceutical companies avoid them. Researchers struggle for grants. Even advocacy groups can’t mobilize around a single name.
Which explains why progress is glacial. The Dutch case was published in 2008. Since then? Barely a whisper. No follow-up studies. No animal models. Just a case report gathering digital dust in a journal archive.
Rarity vs. Impact: Why Some Ultra-Rare Diseases Matter More
Just because a disease is ultra-rare doesn’t mean it’s unimportant. Think of it like this: discovering a new particle in physics might not change daily life, but it reshapes our understanding of the universe. Same here.
Ribose-5-phosphate isomerase deficiency taught scientists something new about metabolic resilience. It revealed how a single enzyme defect can cascade into neurological collapse. That insight could help treat more common disorders—like Alzheimer’s or Parkinson’s—where metabolic dysfunction plays a role.
And that’s the paradox: the rarest diseases often illuminate the most. They’re outliers, yes, but outliers with secrets. That said, most don’t get that far. They vanish into obscurity because no one can justify the cost of looking.
Comparing the Rare: Ultra-Rare vs. Orphan vs. Neglected Diseases
Not all rare diseases are equal in the eyes of medicine or policy. There are nuances—important ones.
Ultra-Rare Diseases: The “N-of-1” Problem
These affect fewer than 50 people worldwide. Often monogenic. Often fatal in childhood. Examples: Ribose-5-phosphate isomerase deficiency, Fields disease, Fibrodysplasia ossificans progressiva (FOP)—which affects about 1 in 2 million (roughly 800 known cases). FOP is a bit like the body turning into stone—muscles and connective tissue slowly ossify. Brutal. But at least it has a name, some research, even a patient registry.
Orphan Diseases: The Regulatory Loophole
The Orphan Drug Act of 1983 in the U.S. incentivizes treatment development for diseases affecting under 200,000 people. Tax credits, market exclusivity, fee waivers. As a result, over 600 orphan drugs have been approved since. But here’s the catch: most target diseases with thousands of patients, not dozens. The real ultra-rare get left behind. The incentives aren’t strong enough.
Neglected Tropical Diseases: Rare in the West, Common Elsewhere
Chagas disease, leishmaniasis, dracunculiasis—these affect millions in low-income countries but fewer than 1,000 in the U.S. They’re “rare” by American standards, but not globally. Yet they’re underfunded because they don’t impact wealthy populations. The problem is not scarcity, but indifference. And no, that’s not the same as ultra-rarity—it’s worse, because it’s preventable.
Frequently Asked Questions
How Do Doctors Diagnose a Disease with Only One Known Case?
Through a mix of clinical observation, metabolic screening, and advanced genetics. In the case of Ribose-5-phosphate isomerase deficiency, abnormal levels of ribitol and D-arabitol in urine were the red flags. Whole-exome sequencing then pinpointed the RPIA mutation. Today, tools like metabolomics and AI-assisted genomic analysis make such diagnoses more likely—but access is uneven. Most hospitals can’t run these tests. So yes, it’s possible, but only if you’re looking in the right place with the right tools.
Can a Disease with One Case Be Cured?
Not in the traditional sense. You can’t run clinical trials. You can’t test therapies on multiple patients. But precision medicine offers hope. For that one Dutch child, a tailored treatment—say, a gene therapy vector designed specifically for their mutation—might have worked. But it would have cost tens of millions. And after that? The treatment dies with the patient. Which raises ethical questions about resource allocation in medicine.
Are There Likely More Undiscovered Ultra-Rare Diseases?
Almost certainly. With 20,000 genes and millions of possible mutations, the potential for unique disorders is astronomical. Some estimates suggest there could be thousands of “private mutations”—genetic errors so rare they appear in only one person. We’re just beginning to detect them. As sequencing becomes cheaper, we’ll find more. But will we care? That’s the real question.
The Bottom Line
I find this overrated, the idea that we’re close to understanding all human disease. We’re not. We’re mapping the edges of a continent we barely knew existed. The rarest disease—whether it’s Ribose-5-phosphate isomerase deficiency or something lurking in a remote village—is a reminder of how much we don’t know.
Yes, that one confirmed case makes it the rarest by default. But rarity isn’t just a number. It’s a reflection of who gets seen, who gets tested, and who gets remembered. And honestly, it is unclear whether we’ll ever truly know the rarest disease—because the moment we do, another might already be forming in silence.
So here’s my take: instead of chasing records, we should chase equity. Invest in global diagnostics. Expand genetic screening. Because the next ultra-rare disease might not stay rare—for long. And that changes everything.